Dana-Farber Cancer Institute, Boston, MA; University of Washington School of Nursing, Seattle, WA.
Dana-Farber Cancer Institute, Boston, MA.
Urol Oncol. 2021 Aug;39(8):493.e9-493.e15. doi: 10.1016/j.urolonc.2020.11.038. Epub 2021 Jan 19.
Men diagnosed with localized prostate cancer must navigate a highly preference-sensitive decision between treatment options with varying adverse outcome profiles. We evaluated whether use of a decision support tool previously shown to decrease decisional conflict also impacted the secondary outcome of post-treatment decision regret.
Participants were randomized to receive personalized decision support via the Personal Patient Profile-Prostate or usual care prior to a final treatment decision. Symptoms were measured just before randomization and 6 months later; decision regret was measured at 6 months along with records review to ascertain treatment choices. Regression modeling explored associations between baseline variables including race and D`Amico risk, study group, and 6-month variables regret, choice, and symptoms.
At 6 months, 287 of 392 (73%) men returned questionnaires of which 257 (89%) had made a treatment choice. Of that group, 201 of 257 (78%) completely answered the regret scale. Regret was not significantly different between participants randomized to the P3P intervention compared to the control group (P = 0.360). In univariate analyses, we found that Black men, men with hormonal symptoms, and men with bowel symptoms reported significantly higher decision regret (all P < 0.01). Significant interactions were detected between race and study group (intervention vs. usual care) in the multivariable model; use of the Personal Patient Profile-Prostate was associated with significantly decreased decisional regret among Black men (P = 0.037). Interactions between regret, symptoms and treatment revealed that (1) men choosing definitive treatment and reporting no hormonal symptoms reported lower regret compared to all others; and (2) men choosing active surveillance and reporting bowel symptoms had higher regret compared to all others.
The Personal Patient Profile-Prostate decision support tool may be most beneficial in minimizing decisional regret for Black men considering treatment options for newly-diagnosed prostate cancer.
NCT01844999.
被诊断为局限性前列腺癌的男性必须在具有不同不良后果风险的治疗方案之间做出高度偏好敏感的决策。我们评估了先前显示可降低决策冲突的决策支持工具的使用是否也会影响治疗后决策后悔的次要结果。
参与者在最终治疗决策前被随机分配接受个性化决策支持(通过个人患者档案-前列腺)或常规护理。症状在随机分组前和 6 个月后进行测量;在 6 个月时,通过记录审查来确定治疗选择,同时测量决策后悔。回归模型探讨了基线变量(包括种族和 D`Amico 风险、研究组)和 6 个月变量(后悔、选择和症状)之间的关联。
在 6 个月时,392 名参与者中有 287 名(73%)返回了问卷,其中 257 名(89%)做出了治疗选择。在该组中,201 名(78%)完全回答了后悔量表。与对照组相比,随机分配到 P3P 干预组的参与者之间的后悔程度没有显著差异(P=0.360)。在单变量分析中,我们发现黑人男性、有激素症状的男性和有肠道症状的男性报告的决策后悔明显更高(均 P<0.01)。在多变量模型中,检测到种族和研究组(干预组与常规护理组)之间存在显著的交互作用;使用个人患者档案-前列腺与黑人男性的决策后悔显著降低相关(P=0.037)。后悔、症状和治疗之间的相互作用表明:(1)选择确定性治疗且无激素症状的男性与其他所有男性相比,后悔程度较低;(2)选择主动监测且有肠道症状的男性与其他所有男性相比,后悔程度较高。
个人患者档案-前列腺决策支持工具对于考虑新诊断前列腺癌治疗方案的黑人男性来说,可能是降低决策后悔的最有效方法。
NCT01844999。